EMA Authorised: Rekambys (rilpivirine) — Janssen-Cilag International NV

View source ↗

Summary

EMA authorised Rekambys (rilpivirine) by Janssen-Cilag International NV for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Rekambys (rilpivirine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Janssen-Cilag International NV. Decision date: 14/08/2025